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ABSTRACT 
Ursodeoxycholic Acid is used in the treatment of Liver disease. An accurate and robust invitro method is developed and validated 
for measurement of drug release in Ursodeoxycholic Acid tablets. HPLC method for quantification of drug in dissolution samples of 
Ursodeoxycholic Acid tablet is developed and validated. Phosphate buffer (0.05M) of pH- 7.5 is used as dissolution medium and 
paddle (USP-II) as apparatus at 75 rpm. The sample was withdrawn after 60 minutes. The developed HPLC method was used for 
quantitative estimation of drug release in dissolution samples of Ursodeoxycholic Acid tablet. The HPLC column of Hypersil - C18, 
250X4.6 mm, 5µm is used. The phosphate buffer of pH – 6.5 and acetonitrile was mixed in the ratio of 50:50v/v pumped at a flow 
rate of 1.0 ml/minute. The detection was made at wavelength of 210 nm. Through method validation it is proved that the method is 
accurate, rugged, precise and robust. The method is linear over the concentration range of 50% – 150%. The method also found very 
precise.  Mean recovery of Ursodeoxycholic Acid was found 99.6 ±38%. 
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INTRODUCTION  
Ursodeoxycholic acid (UDCA), is a bile acid (fig. 1) and 
is generally used for the treatment of liver diseases. 
UDCA is a naturally occurring bile acid and used to 
dissolve gallstones in the gall bladder 
1-4
.  
 
Figure 1: Structure of Ursodeoxycholic Acid  
It is very important to measure the drug release of 
UDCA for better quality of products so that the disease 
can be cured very fast. Hence this research was focused 
to develop dissolution method and measurement of drug 
release accurately in dissolution samples. The 
measurement method is chromatographic method by 
HPLC. There are few methods published currently for 
the estimation of UDCA in Ursodeoxycholic acid 
tablets
5-9
. This method can be used in the quality control 
or in research laboratories of pharmaceutical companies 
for assay determination of Ursodeoxycholic acid tablets. 
The dissolution method along with chromatographic 
method which is used for determination of drug is 
validated as per International Conference on 
Harmonization (ICH) Q2 (R1) and United State of 
Pharmacopoeia (USP) chapter <1225> and chapter 
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. The method found to be precise, accurate, 
linear and robust.  
EXPERIMENTAL 
Materials  
Potassium hydrogen orthophosphate, Sodium hydroxide, 
Acetonitrile and HPLC grade water. 
Method and Instruments 
Dissolution apparatus of Lab India, Waters High 
Performance Liquid Chromatography (HPLC) system 
with UV detector. 
Dissolution method: 
Dissolution Medium: 0.05M Phosphate buffer -pH-7.5 
(900 ml) 
Apparatus: Paddle (USP II) 
Rotation per minute (RPM): 75 RPM 
Time: 60 minutes 
Chromatographic Parameters 
HPLC column: Hypersil - C18, 250 X 4.6 mm, 5µm  
Pump Flow: 1.0 ml/min 
Injection volume: 50.0 µL  
Mobile Phase: Mixture of buffer and Acetonitrile in the 
ratio of 50:50 v/v. 
Wavelength: UV detector at 210nm.  
The column oven temperature: Ambient. 
Preparation of solutions: 
Buffer Solution for mobile phase: 
Dissolved about 6.8 gm of potassium hydrogen 
orthophosphate in 1000 ml of HPLC grade water and 
adjusted the pH to 6.5 with dilute sodium hydroxide. 
Sonicated for degassing and filtered through 0.45 µm 
membrane filter. 
Standard Preparation: 
Weighed accurately about 40mg of UDCA working 
standard and transferred to 100 ml volumetric flask. The 
UDCA was dissolved in 5 ml methanol with sonication 
and intermittent shaking and diluted to volume with 
dissolution medium.  
Dissolution Medium: 
Dissolved 68 gm of potassium dihydrogen 
orthophosphate in 10000 ml of purified water, adjusted 
pH to 7.5 with dilute sodium hydroxide solution. 
Degassed the solution with means of sonication.  
Sample Preparation: 
Placed one tablet in each individual jar (six tablets in six 
individual jars) which was contained 900 ml of 
dissolution medium maintained at 37.0. The paddle was 
rotated at speed of 75 rpm. Aliquot was withdrawn after 
60 minutes. Filtered through 0.45µ filter and injected in 
chromatographic system.  
Procedure:  
Injected blank (dissolution medium), standard solution 
and sample solution in HPLC system using the newly 
developed chromatographic method. The concentration 
of drug release was calculated using sample area against 
standard area. 
Method Validation 
Developed analytical method is validated for parameters 
as suggested by ICH Q2 (R1) and USP. 
System Suitability: 
System suitability test (SST) is very important in liquid 
chromatographic method to prove that the system is 
working accurately and all the chromatographic 
conditions are fine. They are used to verify the 
reproducibility of the chromatographic parameters and 
system is satisfactory for the analysis to be done. The 
system suitability test was performed in accordance with 
USP. 
Specificity: 
Specificity is the ability of the method to measure the 
analyte response in the presence of other substances or 
expected to be present. The specifity of the developed 
LC method was carried out by injecting dissolution 
medium and placebo.  
The diluent (blank), placebo solution was injected in 
sequence for evaluation of specificity of proposed 
method. The chromatograms were monitored for any 
peak eluted at the retention time of drug. 
Precision: 
Precision is a major of the degree of repeatability (intra-
day), intermediate precision and reproducibility (Inter-
day) of the analytical method under normal operating 
circumstances.  
Precision is usually measured as the coefficient of 
variation or relative standard deviation of analytical 
results acquired from independently prepared samples 
(six tablets in case of dissolution). 
Method precision was evaluated by performing the 
dissolution using proposed method (dissolution 
parameters and chromatographic method) on six tablets 
of UDCA tablets and calculated % release of UDCA in 
each sample. The %RSD for set of six tablets was 
calculated.  
The intermediate precision of the method was also 
evaluated using different analyst and a different 
instrument in the same laboratory by carrying out 
dissolution on six more tablets using proposed method 
and calculated % release of UDCA in each sample. 
Calculated the %RSD for 12 results. The acceptance 
criteria for %RSD was not more than 5% and the 
absolute difference between results by two analysts was 
not more than 5%. 
Recovery (accuracy): 
Accuracy is the closeness of agreement between test 
results and the accepted reference value. The accuracy 
of the method was performed by recovery studies. 
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In order to evaluate the accuracy of the proposed 
method, recovery test was performed by adding known 
amount of standard solution to the placebo formulation 
sample, followed by analysis using the proposed 
dissolution parameters and chromatographic method. 
The recovery studies were done at three different levels 
at 50%, 100% and 150% with three determinations of 
working level concentration using standard spiking 
method in placebo. 
All the above solutions were prepared in duplicate; the 
sample aliquots were withdrawn after 60 minutes and 
were analyzed using proposed chromatographic 
condition. The recovery at each level was calculated by 
using the theoretical value from exact weight taken for 
spiking. The % recovery was calculated with respect to 
amount added. The acceptance criteria for % recovery 
were – the recovery at each level should be in the range 
of 95% to 105% and overall %RSD of nine results 
should be less than 5%.  
Linearity: 
The linearity of an analytical method is its ability to 
elicit test results that are directly or by means of well-
defined mathematical transformations, proportional to 
the concentration of analytes in the samples within a 
given range. 
The linearity plot was constructed for UDCA in the 
concentration range of 50% to 150% of the sample 
concentration (390 µg/ml). The primary stock solution 
of UDCA working standard was prepared. From the 
primary stock solution, appropriate dilutions were made 
to get concentration of 190, 290, 390, 490 and 590 
µg/ml. The calibration curve was plotted as 
concentration of the respective drug solutions verses the 
peak area at each level. The results were statistically 
evaluated and correlation coefficient determination, 
slope and y-intercept values were calculated. 
Robustness: 
Robustness is a capacity of a method to remain 
unaffected by small deliberate changes in method 
parameters. 
For robustness study, the standard concentration 550 
µg/ml of UDCA was used. Following chromatographic 
parameters were considered for the robustness study. 
 Effect of acetonitrile in mobile phase composition 
(±2%) 
 Effect of flow rate (±0.1ml/min) 
 Effect of wavelength (±2nm) 
The robustness of dissolution method was also evaluated 
by making deliberate changes in the dissolution 
parameters and analysis was performed using the 
proposed chromatographic method. The below 
dissolution parameters were changed during this study; 
 Change in pH of dissolution medium ± 0.1 
 Change in RPM ± 3 RPM 
Solution stability of sample and standard in 
dissolution medium: 
The solution stability of sample and standard solution in 
dissolution medium was performed to understand the 
stability which will be helpful for sample handling 
during routine analysis in laboratory by using the 
proposed method.  
Solution stability was carried out for sample solution at 
2-8 and ambient temperature for 24 hr. The sample and 
standard solution were injected immediately after 
preparation in the HPLC system considering it as an 
initial (0 hr.) as baseline. 
RESULTS AND DISCUSSION 
Method Development 
Literature survey revealed that UDCA is having 
molecular weight 392.58 g/mol. The UDCA solution of 
400 µg/ml concentration prepared in dissolution 
medium was scanned on PDA and the spectra of UDCA 
was recorded. It was observed that UDCA doesn’t have 
good absorption after 210nm. Hence to detect the drug 
adequately the wavelength of 210nm was selected as 
detection wavelength. 
The blank (dissolution medium), placebo solution and 
sample solution was injected in HPLC system by using 
stationary phase C18 to check the interference due to 
diluent or placebo in main drug. The column of make 
Hypersil (C18, 250 X 4.6 mm, 5µ) was found suitable. 
To achieve the optimum run time and capacity factor 
different compositions of organic modifier with buffer 
were tried at different pH buffer.  The elution pattern of 
the UDCA was studied.  
Method Validation 
Specificity: 
The chromatograms during specificity study (fig. 2, 3 
and 4) of diluent, placebo and sample solution shows 
that there is no co elution of any peak with UDCA due 
to blank and placebo. 
 
Figure 2: Blank Chromatogram 
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Figure 3: Standard Chromatogram 
 
Figure 4: Standard Chromatogram 
Precision: 
System Precision: 
The system precision was evaluated by injecting six 
standard solutions in HPLC by using the proposed 
chromatographic conditions and the % RSD of Area and 
retention time was calculated. The %RSD of area was 
found 0.85%, and %RSD of retention time was found 
0.43%. 
Method Precision: 
Method precision was divided in two parts as below; 
Intraday precision: Intraday precision was evaluated by 
performing dissolution of Ursodeoxycholic acid 300 mg 
tablets on six tablets (n=6) using the proposed 
dissolution and chromatographic parameters, % drug 
release was calculated. The %RSD for six results (of six 
tablets) was calculated and found 1.6%.  
Inter-day precision (Ruggedness): 
The ruggedness of the method was evaluated by 
performing dissolution of Ursodeoxycholic acid 300 mg 
tablets on six tablets (n=6) using the proposed 
dissolution and chromatographic parameters on different 
day and on different instrument. The % drug release was 
calculated and %RSD of six results was found 1.5%. 
The inter-day precision for two sets (n=12) for their 
%recovery was found to be 1.5%. The absolute 
difference between results for intermediate precision 
was found 2% (table 1). 
 
Table 1: Method Precision results 
Sample  No. % Dissolution (Precision) % Dissolution (Intermediate Precision) 
1 98 95 
2 96 96 
3 99 99 
4 98 95 
5 100 96 
6 96 96 
Mean 98 96 
%RSD 1.6 1.5 
Overall mean 97 
Over all %RSD 1.5 
Absolute difference of assay results 2% 
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Accuracy (Recovery): 
The % recovery at 50%, 100% and 150% was found to 
be 99.4±0.38, 99.6± 0.36 and 99.8± 0.35% respectively 
(table 3). The overall mean recovery was found to be 
99.6± 0.38%. The recovery results were found within 
acceptance criteria (table 3). The developed method 
found to be accurate for determination of drug release of 
UDCA in dissolution samples of Ursodeoxycholic Acid 
tablets.
 
Table 2: Accuracy 
Level Sample no. % Recovery Mean %RSD 
 
50% 
1 99.2 99.4 0.38 
2 99.8 
3 99.1 
 
100% 
1 99.5 99.6 0.36 
2 100.0 
3 99.3 
 
150% 
1 99.5 99.8 0.35 
2 99.8 
3 100.2 
Over all mean and %RSD  99.6 0.38 
 
Linearity: 
Linearity was evaluated at five different (50% to 150%) 
level considering the working concentration level as 
100%. The area response of UDCA drug against 
concentration at five different level was performed in 
the range of 50% – 150% and response for UDCA found 
to be linear. The correlation coefficient (r) was found to 
be 0.999. The linearity was found with in acceptance 
criteria. 
Robustness: 
The robustness of the method was verified by making 
the deliberate changes in the critical chromatographic 
parameters and the system suitability was checked. 
Below chromatographic parameters (one parameter at a 
time) were changed. 
 Organic modifier composition 
 Pump flow rate  
 Column oven temperature  
The results are presented in table -3 and found within 
the acceptance criteria.
 
Table 3: Robustness Results for chromatographic parameter 
HPLC Parameter % RSD of standard 
Initial  As per actual method 0.62 
Acetonitrile composition in mobile 
phase (± 2%) 
+2% (52%) 0.45 
-2% (48%) 0.52 
Pump flow rate ± 0.1 ml/min 1.1 ml/min 0.44 
0.9 ml/min 0.21 
Wavelength ± 2nm 208 nm 0.15 
212 nm 0.24 
 
The robustness of the dissolution method was evaluated 
by making the changes in proposed dissolution 
parameters.  
The results are presented in table -4 and found within 
the acceptance criteria.
 
Table 4: Robustness results for dissolution parameter 
Dissolution Parameter % Average Drug Release %RSD of six tablets 
Initial  As per actual method 95 2.8 
pH of Dissolution Medium  
(± 0.1) 
+0.1 (7.6) 97 3.2 
-0.1 (7.4) 92 2.9 
Rotation of paddle per minute 
± 0.1 ml/min 
+3 (78 RPM) 93 1.8 
- 3 (72 RPM) 95 3.0 
 
Solution Stability of Sample and Standard 
The Ursodeoxycholic Acid sample found to be stable up 
to 24 hours in dissolution medium at ambient 
temperature. The average % results after 24 hours were 
found to be 95%. 
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Application of developed method: 
The proposed dissolution method with chromatographic 
method was used for measurement of % drug release of 
Ursodeoxycholic Acid tablets 500mg, the results were 
found within the specification. The proposed method can 
be used in laboratory for dissolution of Ursodeoxycholic 
Acid tablets. 
CONCLUSION 
The proposed HPLC method is accurate, linear, precise 
and rugged methodology for quantitative determination 
(Assay) of Ursodeoxycholic Acid in Ursodeoxycholic 
Acid tablets of different strengths. The results of the 
method validation study show that the method is 
accurate and linear in the concentration range of 50%-
150 % of Ursodeoxycholic Acid. The analytical method 
validation was done as per ICH Q2(R1) and USP 
guidelines. This method can be used by quality control 
or research laboratories for quantitative determination of 
the content (assay) of Ursodeoxycholic Acid tablets of 
different strength. 
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